A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Latest Information Update: 13 Oct 2023
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Laryngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms SMART-KEY
- 04 Oct 2023 Planned number of patients changed from 42 to 43.
- 04 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Study design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.